13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001791827
Total reported value
$624.4M
$624.4M
55 檔
25.4%
The Q2 2025 SEC filing reveals that Avidity Partners Management LP held a total portfolio value of $624.4M, covering 55 public equity positions.
Avidity Partners Management LP executed strategic sector rebalancing during Q2 2025, establishing 16 new positions while fully exiting 25 holdings and trimming 13 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 7.77% | -1.75% | +52.91% | |
| 2 | BSX | Boston Scientific CORP | Stock-Healthcare | 6.89% | -0.21% | -4.23% | |
| 3 | NTRA | Natera Inc | Stock-Healthcare | 6.71% | -0.36% | EXIT | |
| 4 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 6.47% | -2.91% | +1.28% | |
| 5 | EXK | Exact Sciences CORP | Stock-Materials | 3.76% | — | +0.57% | |
| 6 | THC | Tenet Healthcare CORP | Stock-Healthcare | 3.72% | — | +47.22% | |
| 7 | DXCM | Dexcom Inc | Stock-Healthcare | 3.66% | -0.06% | +16.94% | |
| 8 | DHR | Danaher CORP | Stock-Healthcare | 3.53% | — | +101.57% | |
| 9 | HNGE | Hinge Health Inc-a | Stock-Other | 3.32% | — | — | |
| 10 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.93% | — | — | |
| 11 | GMAB | Genmab A/s -sp Adr | Stock-Other | 2.68% | -0.05% | +50.08% | |
| 12 | RGEN | Repligen CORP | Stock-Healthcare | 2.64% | -0.16% | — | |
| 13 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 2.39% | — | +90.97% | |
| 14 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 2.30% | -1.66% | +43.35% | |
| 15 | JBIO | Jade Biosciences Inc | Stock-Other | 2.24% | +2.06% | — | |
| 16 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 2.03% | -0.21% | +33.06% | |
| 17 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.99% | -0.21% | EXIT | |
| 18 | MCK | Mckesson CORP | Stock-Healthcare | 1.97% | — | — | |
| 19 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.97% | — | +22.73% | |
| 20 | COR | Cencora Inc | Stock-Healthcare | 1.96% | — | -16.54% | |
| 21 | HQY | Healthequity Inc | Stock-Healthcare | 1.92% | — | +17.95% | |
| 22 | EHC | Encompass Health CORP | Stock-Healthcare | 1.81% | -0.14% | — | |
| 23 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.68% | -0.30% | EXIT | |
| 24 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.42% | — | +135.09% | |
| 25 | OMDA | Omada Health Inc | Stock-Other | 1.42% | — | — | |
| 26 | BEAM | Beam Therapeutics Inc | Stock-Other | 1.39% | — | -42.30% | |
| 27 | HUM | Humana Inc | Stock-Healthcare | 1.34% | — | -82.86% | |
| 28 | CATX | Perspective Therapeutics Inc | Stock-Other | 1.27% | -1.67% | -15.41% | |
| 29 | OGN | Organon & Co | Stock-Healthcare | 1.23% | — | +19.63% | |
| 30 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.20% | +0.12% | NEW | |
| 31 | INSM | Insmed Inc | Stock-Healthcare | 1.18% | — | -44.86% | |
| 32 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.15% | — | — | |
| 33 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.12% | — | -52.19% | |
| 34 | CNTX | Context Therapeutics Inc | Stock-Other | 0.98% | -2.21% | +0.00% | |
| 35 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.91% | — | -63.02% | |
| 36 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.79% | +4.04% | — | |
| 37 | VTLUSD | Immunic Inc | Stock-Other | 0.78% | -1.51% | EXIT | |
| 38 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.75% | — | — | |
| 39 | DOCS | Doximity Inc-class A | Stock-Healthcare | 0.73% | — | -51.02% | |
| 40 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.67% | — | -52.89% | |
| 41 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.64% | — | — | |
| 42 | QURE | uniQure N.V. | Stock-Other | 0.57% | — | -38.43% | |
| 43 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.56% | — | — | |
| 44 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.53% | — | — | |
| 45 | CAH | Cardinal Health Inc | Stock-Healthcare | 0.50% | — | — | |
| 46 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.49% | — | — | |
| 47 | 2KZ0 | Kezar Life Sciences Inc | Stock-Other | 0.46% | — | — | |
| 48 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.43% | +0.01% | — | |
| 49 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.37% | -0.19% | EXIT | |
| 50 | ARVN | Arvinas Inc | Stock-Other | 0.36% | — | -79.09% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | +3.5% | +67.20% | Add |
| 2 | HNGE | Hinge Health Inc-a | +3.3% | NEW | New buy |
| 3 | CGON | Cg Oncology Inc | +3.2% | +52.91% | Add |
| 4 | ISRG | Intuitive Surgical Inc | +2.9% | NEW | New buy |
| 5 | RGEN | Repligen CORP | +2.6% | NEW | New buy |
| 6 | JBIO | Jade Biosciences Inc | +2.2% | NEW | New buy |
| 7 | MCK | Mckesson CORP | +2% | NEW | New buy |
| 8 | THC | Tenet Healthcare CORP | +1.9% | +47.22% | Add |
| 9 | EHC | Encompass Health CORP | +1.8% | NEW | New buy |
| 10 | DHR | Danaher CORP | +1.8% | +101.57% | Add |
| 11 | OMDA | Omada Health Inc | +1.4% | NEW | New buy |
| 12 | DXCM | Dexcom Inc | +1.3% | +16.94% | Add |
| 13 | MDGL | Madrigal Pharmaceuticals Inc | +1.2% | NEW | New buy |
| 14 | PHAT | Phathom Pharmaceuticals Inc | +1.1% | +33.06% | Add |
| 15 | GMAB | Genmab A/s -sp Adr | +1.1% | +50.08% | Add |
| 16 | AKRO | Akero Therapeutics Inc | +1% | +135.09% | Add |
| 17 | TMO | Thermo Fisher Scientific Inc | +0.9% | +90.97% | Add |
| 18 | TEVA | Teva Pharmaceutical-sp Adr | +0.9% | +43.35% | Add |
| 19 | EXK | Exact Sciences CORP | +0.9% | +0.57% | Add |
| 20 | ARQT | Arcutis Biotherapeutics Inc | +0.8% | NEW | New buy |
| 21 | BBIO | Bridgebio Pharma Inc | +0.7% | +86.67% | Add |
| 22 | VRNA | Verona Pharma PLC - Adr | +0.6% | NEW | New buy |
| 23 | HQY | Healthequity Inc | +0.6% | +17.95% | Add |
| 24 | APGE | Apogee Therapeutics Inc | +0.6% | NEW | New buy |
| 25 | DNTH | Dianthus Therapeutics Inc | +0.5% | +1.28% | Add |
| 26 | CAH | Cardinal Health Inc | +0.5% | NEW | New buy |
| 27 | SPRY | Ars Pharmaceuticals Inc | +0.5% | NEW | New buy |
| 28 | NTLA | Intellia Therapeutics Inc | +0.4% | NEW | New buy |
| 29 | BSX | Boston Scientific CORP | +0.4% | -4.23% | Trim |
| 30 | CATX | Perspective Therapeutics Inc | +0.4% | -15.41% | Trim |
| 31 | MLTX | Moonlake Immunotherapeutics | +0.4% | NEW | New buy |
| 32 | AXSM | Axsome Therapeutics Inc | +0.3% | +22.73% | Add |
| 33 | RVMD | Revolution Medicines Inc | +0.2% | +7.32% | Add |
| 34 | CNTX | Context Therapeutics Inc | +0.1% | +0.00% | Add |
| 35 | ORKA | Oruka Therapeutics Inc | +0.1% | — | Unchanged |
| 36 | SLNOEUR | Soleno Therapeutics Inc | +0.1% | — | Unchanged |
| 37 | ALT | Altimmune Inc | +0.1% | NEW | New buy |
| 38 | KPTI | Karyopharm Therapeutics Inc | 0% | — | Unchanged |
| 39 | ELVN | Enliven Therapeutics Inc | 0% | — | Unchanged |
| 40 | 2KZ0 | Kezar Life Sciences Inc | 0% | — | Unchanged |
| 41 | ✓ | Reviva Pharmaceutcls Hldgs I | 0% | — | Unchanged |
| 42 | HYPR | Hyperfine Inc | 0% | EXIT | Sold out |
| 43 | SCYXEUR | Scynexis Inc | -0.1% | — | Unchanged |
| 44 | QURE | uniQure N.V. | -0.1% | -38.43% | Trim |
| 45 | COR | Cencora Inc | -0.1% | -16.54% | Trim |
| 46 | VTLUSD | Immunic Inc | -0.2% | +26.07% | Add |
| 47 | PCVX | Vaxcyte Inc | -0.2% | EXIT | Sold out |
| 48 | AGL | agilon health, inc. | -0.3% | EXIT | Sold out |
| 49 | NAMS | NewAmsterdam Pharma Company N.V. | -0.3% | EXIT | Sold out |
| 50 | OGN | Organon & Co | -0.3% | +19.63% | Add |
According to official SEC Form 13F filings, Avidity Partners Management LP reported a total U.S. public equity portfolio value of $624.4M across 55 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CGON, BSX, NTRA) accounted for 25.4% of total reported equity market value during Q2 2025.
Top New Position Initiated
HNGE
市值: $16.7M
Top Position Liquidated / Trimmed
REGN
前期市值: $16.1M
During Q2 2025, Avidity Partners Management LP's top holdings by market value included CGON (7.8%)、BSX (6.9%)、NTRA (6.7%). The largest single position, CGON, represented 7.8% of total portfolio value.
In Q2 2025, Avidity Partners Management LP made 73 total portfolio adjustments, initiating 16 new buys, adding to 19 positions, trimming 13 holdings, and fully liquidating 25 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.